Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367059080> ?p ?o ?g. }
- W4367059080 abstract "Abstract Background . Diabetic patients presenting with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) have an increased risk of contrast-induced-acute kidney injury (CI-AKI). It has been shown that sodium-glucose cotransporter-2 inhibitors (SGLT2-I) have a nephroprotective effect. Purpose . To analyze the association between chronic SGLT2-I treatment and the development of CI-AKI in diabetic patients with AMI (both ST- and non-ST segment elevation myocardial infarction) treated with PCI, in both patients with and without chronic kidney disease (CKD). Methods . In this multicenter international registry, consecutive patients with type 2 diabetes mellitus (T2DM) and AMI undergoing PCI between 2018 and 2021 were enrolled. The study population was stratified by the presence of CKD and anti-diabetic therapy at admission (SGLT2-I versus non-SGLT2-I users). CI-AKI was defined as an absolute (≥0.5 mg/dl) or relative increase (≥25%) in creatinine at 48-72 h after PCI compared to baseline values. Results . The study population consisted of 646 AMI patients: 111 SGLT2-I users [28 (25.2%) with CKD] and 535 non-SGLT2-I users [221 (41.3%) with CKD]. The median age was 70 [61-79] years, and more than 77% were males. Independently of creatinine at admission, SGLT2-I users exhibited significantly lower creatinine values at 72h after PCI, both in the non-CKD and CKD stratum. After PCI, the overall rate of CI-AKI was 76 (11.8%), significantly lower in SGLT2-I users compared to non-SGLT2-I patients (5.4% vs 13.1%, p=0.022). This finding was confirmed also in patients without CKD (p=0.040). In the CKD cohort, SGLT2-I users maintained significantly lower creatinine values at discharge, albeit without significant differences in CI-AKI rate compared to non-SGLT2-I patients. At multivariate analysis, the use of SGLT2-I was identified as an independent predictor of reduced rate of CI-AKI (OR 0.356; 95%CI 0.134-0.943, p=0.038). Patients with CI-AKI reported a longer hospital stay and higher incidence of adverse cardiovascular events at follow-up (p=0.001), mostly in the CKD cohort. Conclusion . In T2DM patients with AMI, the use of SGLT2-I was associated with a lower risk of CI-AKI during the index hospitalization, mostly in patients without CKD. Our results provide new insights into the cardio and nephroprotective effects of SGLT2-I in the setting of AMI. Trial Registration: data are part of the observational Registry: SGLT2-I AMI PROTECT. ClinicalTrials.gov Identifier: NCT 05261867." @default.
- W4367059080 created "2023-04-27" @default.
- W4367059080 creator A5000200390 @default.
- W4367059080 creator A5008145401 @default.
- W4367059080 creator A5008826996 @default.
- W4367059080 creator A5015308570 @default.
- W4367059080 creator A5019034390 @default.
- W4367059080 creator A5025539088 @default.
- W4367059080 creator A5027649822 @default.
- W4367059080 creator A5030742489 @default.
- W4367059080 creator A5033930135 @default.
- W4367059080 creator A5035487463 @default.
- W4367059080 creator A5041787832 @default.
- W4367059080 creator A5046810967 @default.
- W4367059080 creator A5049040367 @default.
- W4367059080 creator A5049432842 @default.
- W4367059080 creator A5063580570 @default.
- W4367059080 creator A5065469571 @default.
- W4367059080 creator A5067676269 @default.
- W4367059080 creator A5067713609 @default.
- W4367059080 creator A5068323275 @default.
- W4367059080 creator A5069163875 @default.
- W4367059080 creator A5072890280 @default.
- W4367059080 creator A5074863220 @default.
- W4367059080 creator A5078420807 @default.
- W4367059080 creator A5084550471 @default.
- W4367059080 creator A5088545874 @default.
- W4367059080 date "2023-04-26" @default.
- W4367059080 modified "2023-10-14" @default.
- W4367059080 title "Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in Diabetic patients with Acute Myocardial Infarction: Insight from SGLT2-I AMI PROTECT Registry" @default.
- W4367059080 cites W2042074736 @default.
- W4367059080 cites W2079433011 @default.
- W4367059080 cites W2084539319 @default.
- W4367059080 cites W2116898738 @default.
- W4367059080 cites W2128803585 @default.
- W4367059080 cites W2153104532 @default.
- W4367059080 cites W2159718794 @default.
- W4367059080 cites W2424539745 @default.
- W4367059080 cites W2626446274 @default.
- W4367059080 cites W2754054868 @default.
- W4367059080 cites W2767197149 @default.
- W4367059080 cites W2792588444 @default.
- W4367059080 cites W2800723402 @default.
- W4367059080 cites W2900413769 @default.
- W4367059080 cites W2906107202 @default.
- W4367059080 cites W2939222610 @default.
- W4367059080 cites W2947687368 @default.
- W4367059080 cites W3088173406 @default.
- W4367059080 cites W3162195278 @default.
- W4367059080 cites W4200227148 @default.
- W4367059080 cites W4280507712 @default.
- W4367059080 cites W4280549607 @default.
- W4367059080 cites W4286630686 @default.
- W4367059080 cites W4294751438 @default.
- W4367059080 cites W4297369808 @default.
- W4367059080 cites W4306783500 @default.
- W4367059080 cites W4310673842 @default.
- W4367059080 cites W4318982565 @default.
- W4367059080 cites W4365457321 @default.
- W4367059080 doi "https://doi.org/10.21203/rs.3.rs-2841577/v1" @default.
- W4367059080 hasPublicationYear "2023" @default.
- W4367059080 type Work @default.
- W4367059080 citedByCount "0" @default.
- W4367059080 crossrefType "posted-content" @default.
- W4367059080 hasAuthorship W4367059080A5000200390 @default.
- W4367059080 hasAuthorship W4367059080A5008145401 @default.
- W4367059080 hasAuthorship W4367059080A5008826996 @default.
- W4367059080 hasAuthorship W4367059080A5015308570 @default.
- W4367059080 hasAuthorship W4367059080A5019034390 @default.
- W4367059080 hasAuthorship W4367059080A5025539088 @default.
- W4367059080 hasAuthorship W4367059080A5027649822 @default.
- W4367059080 hasAuthorship W4367059080A5030742489 @default.
- W4367059080 hasAuthorship W4367059080A5033930135 @default.
- W4367059080 hasAuthorship W4367059080A5035487463 @default.
- W4367059080 hasAuthorship W4367059080A5041787832 @default.
- W4367059080 hasAuthorship W4367059080A5046810967 @default.
- W4367059080 hasAuthorship W4367059080A5049040367 @default.
- W4367059080 hasAuthorship W4367059080A5049432842 @default.
- W4367059080 hasAuthorship W4367059080A5063580570 @default.
- W4367059080 hasAuthorship W4367059080A5065469571 @default.
- W4367059080 hasAuthorship W4367059080A5067676269 @default.
- W4367059080 hasAuthorship W4367059080A5067713609 @default.
- W4367059080 hasAuthorship W4367059080A5068323275 @default.
- W4367059080 hasAuthorship W4367059080A5069163875 @default.
- W4367059080 hasAuthorship W4367059080A5072890280 @default.
- W4367059080 hasAuthorship W4367059080A5074863220 @default.
- W4367059080 hasAuthorship W4367059080A5078420807 @default.
- W4367059080 hasAuthorship W4367059080A5084550471 @default.
- W4367059080 hasAuthorship W4367059080A5088545874 @default.
- W4367059080 hasBestOaLocation W43670590801 @default.
- W4367059080 hasConcept C126322002 @default.
- W4367059080 hasConcept C134018914 @default.
- W4367059080 hasConcept C159641895 @default.
- W4367059080 hasConcept C164705383 @default.
- W4367059080 hasConcept C2778653478 @default.
- W4367059080 hasConcept C2780306776 @default.
- W4367059080 hasConcept C2780400711 @default.
- W4367059080 hasConcept C2780472472 @default.
- W4367059080 hasConcept C2908647359 @default.
- W4367059080 hasConcept C45393284 @default.